Ikarian Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

Ikarian Capital’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-250,000	Closed	-$5.75M	–	201
2025 Q4	$5.75M	Buy	+250,000	New	+$8.22M	0.45%	60
2025 Q3	–	Sell	-563,100	Closed	-$20.5M	–	188
2025 Q2	$20.5M	Buy	563,100 +450,000	+398%	+$16.2M	3.93%	3
2025 Q1	$4.1M	Buy	+113,100	New	+$4.71M	0.5%	41
2020 Q3	–	Sell	-73,500	Closed	-$5.75M	–	204
2020 Q2	$5.75M	Sell	73,500 -26,500	-27%	-$1.75M	0.46%	62
2020 Q1	$4.44M	Buy	+100,000	New	+$5.19M	0.33%	68

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Ikarian Capital's RARE Position: Q2 2026 in Review

Ikarian Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 66% in Q2 2026, selling an estimated $7.87M and leaving 165,617 shares worth $5.53M. The position accounts for 0.6% of the portfolio, ranked #50.

Ikarian Capital first reported a position in RARE in Q4 2019 and has held it in 11 quarters since. The position peaked at $10.1M in Q1 2026. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Ikarian Capital held 165,617 shares of Ultragenyx Pharmaceutical worth $5.53M as of Q2 2026.
Ikarian Capital sold 316,954 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $7.87M.
Ultragenyx Pharmaceutical made up 0.6% of Ikarian Capital's portfolio in Q2 2026, its #50 holding.
Ikarian Capital first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and has held it in 11 quarters since.
Ikarian Capital's Ultragenyx Pharmaceutical position peaked at $10.1M in Q1 2026.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.